Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8345375 | 1.00 | NAAA (0.54) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL8348108 | 1.00 | NAAA (0.54) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL21000274 | 0.88 | CTSL (0.44) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL17597799 | 0.86 | NAAA (0.48) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL21570682 | 0.85 | CTSL (0.47) | NAAACTSLCTSBCTSKOPRM1 | |
| Ammonia Solution, Strong SCHEMBL8053075 | 0.84 | NAAA (0.47) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL27571563 | 0.84 | CTSL (0.41) | NAAACTSLCTSBCTSKOPRM1 | |
| SCHEMBL22762091 | 0.84 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL17103670 | 0.84 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL17103669 | 0.84 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4436667-B1 | PIPERAZINYLSULFONYLARYL COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2026-01-21 | — | — | EP | disclosed |
| EP-4651954-A1 | INHIBITORS OF MPTP | NRG Therapeutics LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| WO-2025103502-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-2124944-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008111010-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-09-18 | — | — | WO | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-6001841-A | ANTISENSE DIAGNOSTICS, THERAPEUTICS AND RESEARCH REAGENTS. | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0352013-B1 | Hydroxymethyl cyclobutyl purines | SQUIBB & SONS INC (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0689460-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5369098-A | Viricides | E. R. SQUIBB & SONS, INC. (US) | 1994-11-29 | — | — | US | disclosed |
| US-5359044-A | Diagnosis, chemical intermediates | ISIS PHARMACEUTICALS (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994019023-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | NAAA 3703/4885CTSL 1675/4885CTSB 3302/4885 |
| US-12539292-B2 | BRM targeting compounds and associated methods of use | ADRM1, SUMO2, BAZ1A | NAAA 3482/4885CTSL 3970/4885CTSB 3573/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | NAAA 4003/4885CTSL 3195/4885CTSB 2435/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | NAAA 4780/4885CTSL 3380/4885CTSB 3026/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | NAAA 4831/4885CTSL 2930/4885CTSB 3803/4885 |
| US-20260041671-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, VHL, BAZ1A | NAAA 4311/4885CTSL 4291/4885CTSB 4061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.